Talquetamab Efficacy in Multiple Myeloma Shown Over 3 Years

Aug 6, 2026 · Published in: Blood

Background Information

Long-term talquetamab offers hope for relapsed/refractory multiple myeloma.

Talquetamab is a novel treatment for patients with relapsed/refractory multiple myeloma, offering new options where current therapies may fail. The overall response rate was 67-74%, with a complete response rate of 33-42%. Median overall survival was up to 34 months in some cohorts. The study shows promise for talquetamab in providing durable responses and a manageable safety profile, although its relevance to emergency medicine is limited. Talquetamab shows long-term efficacy and safety in relapsed/refractory multiple myeloma.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Rasche L, Schinke C, Touzeau C, Minnema MC, van de Donk N, Rodriguez-Otero P, Mateos MV, Ye JC, Tomlinson C, Vishwamitra D, Singh I, Qin X, Campagna M, Masterson T, Vreys V, Lau BW, Tolbert J, Renaud T, Heuck C, Chari A

Citation: Rasche L, Schinke C, Touzeau C, et al. Talquetamab in patients with relapsed/refractory multiple myeloma: 3-year follow-up of the phase 1/2 MonumenTAL-1 study. Blood. 2026. doi:10.1182/blood.2025031994

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

Deep Analysis Pending

The full analysis for this article is being written and reviewed. Every analysis is checked by a licensed pharmacist before it publishes.